;PMID: 11708799 ;source_file_1867.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..55] = [t:0..55] ;1)sentence:[e:61..166] = [t:61..166] ;2)section:[e:170..279] = [t:170..279] ;3)section:[e:283..443] = [t:283..443] ;4)sentence:[e:447..669] = [t:447..669] ;5)sentence:[e:670..881] = [t:670..881] ;6)sentence:[e:882..1114] = [t:882..1114] ;7)sentence:[e:1115..1298] = [t:1115..1298] ;8)sentence:[e:1299..1579] = [t:1299..1579] ;9)sentence:[e:1580..1732] = [t:1580..1732] ;10)sentence:[e:1733..1866] = [t:1733..1866] ;11)sentence:[e:1867..2067] = [t:1867..2067] ;12)sentence:[e:2068..2192] = [t:2068..2192] ;13)sentence:[e:2193..2355] = [t:2193..2355] ;14)sentence:[e:2356..2521] = [t:2356..2521] ;15)section:[e:2522..2552] = [t:2522..2552] ;16)section:[e:2556..2601] = [t:2556..2601] ;section 0 Span:0..55 ;Biochem Biophys Res Commun. 2001 Nov 23;289(1):198-204. (SEC (FRAG (NNP:[0..7] Biochem) (NNP:[8..15] Biophys) (NNP:[16..19] Res) (NNP:[20..26] Commun) (.:[26..27] .) (CD:[28..32] 2001) (IN:[33..36] Nov) (CD:[37..43] 23;289) (-LRB-:[43..44] -LRB-) (CD:[44..45] 1) (-RRB-:[45..46] -RRB-) (CD:[46..54] :198-204) (.:[54..55] .))) ;sentence 1 Span:61..166 ;Tributyltin or triphenyltin inhibits aromatase activity in the human ;granulosa-like tumor cell line KGN. ;[61..72]:substance:"Tributyltin" ;[76..88]:substance:"triphenyltin" ;[98..107]:substance:"aromatase" (SENT (S-HLN (NP-SBJ (NN:[61..72] Tributyltin) (CC:[73..75] or) (NN:[76..88] triphenyltin)) (VP (VBZ:[89..97] inhibits) (NP (NN:[98..107] aromatase) (NN:[108..116] activity)) (PP-LOC (IN:[117..119] in) (NP (NP (DT:[120..123] the) (ADJP (NML (JJ:[124..129] human) (NN:[131..140] granulosa)) (HYPH:[140..141] -) (JJ:[141..145] like)) (NN:[146..151] tumor) (NN:[152..156] cell) (NN:[157..161] line)) (NP (NN:[162..165] KGN))))) (.:[165..166] .))) ;section 2 Span:170..279 ;Saitoh M, Yanase T, Morinaga H, Tanabe M, Mu YM, Nishi Y, Nomura M, Okabe T, ;Goto K, Takayanagi R, Nawata H. (SEC (FRAG (NNP:[170..176] Saitoh) (NNP:[177..179] M,) (NNP:[180..186] Yanase) (NNP:[187..188] T) (,:[188..189] ,) (NNP:[190..198] Morinaga) (NNP:[199..201] H,) (NNP:[202..208] Tanabe) (NNP:[209..211] M,) (NNP:[212..214] Mu) (NNP:[215..217] YM) (,:[217..218] ,) (NNP:[219..224] Nishi) (NNP:[225..226] Y) (,:[226..227] ,) (NNP:[228..234] Nomura) (NNP:[235..237] M,) (NNP:[238..243] Okabe) (NNP:[244..245] T) (,:[245..246] ,) (NNP:[248..252] Goto) (NNP:[253..255] K,) (NNP:[256..266] Takayanagi) (NNP:[267..268] R) (,:[268..269] ,) (NNP:[270..276] Nawata) (NNP:[277..279] H.))) ;section 3 Span:283..443 ;Department of Medicine and Bioregulatory Science, Graduate School of Medical ;Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, ;Japan. (SEC (FRAG (NNP:[283..293] Department) (IN:[294..296] of) (NNP:[297..305] Medicine) (CC:[306..309] and) (NNP:[310..323] Bioregulatory) (NNP:[324..331] Science) (,:[331..332] ,) (NNP:[333..341] Graduate) (NNP:[342..348] School) (IN:[349..351] of) (NNP:[352..359] Medical) (NNPS:[361..369] Sciences) (,:[369..370] ,) (NNP:[371..377] Kyushu) (NNP:[378..388] University) (,:[388..389] ,) (CD:[390..395] 3-1-1) (NNP:[396..404] Maidashi) (,:[404..405] ,) (NNP:[406..414] Higashi-) (NN:[414..416] ku) (,:[416..417] ,) (NNP:[418..425] Fukuoka) (CD:[426..434] 812-8582) (,:[434..435] ,) (NNP:[437..442] Japan) (.:[442..443] .))) ;sentence 4 Span:447..669 ;The superimposition of male sex organs (penis and vas deferens) in a female ;gastropod, called imposex, is widely attributed to the exposure to ;tributyltin (TBT) compounds, used world-wide in antifouling paints for ;ships. ;[591..619]:substance:"tributyltin (TBT) compounds" (SENT (S (NP-SBJ-1 (NP (NP (DT:[447..450] The) (NN:[451..466] superimposition)) (PP (IN:[467..469] of) (NP (NP (JJ:[470..474] male) (NN:[475..478] sex) (NNS:[479..485] organs)) (PRN (-LRB-:[486..487] -LRB-) (NP (NP (NN:[487..492] penis)) (CC:[493..496] and) (NP (NN:[497..500] vas) (NN:[501..509] deferens))) (-RRB-:[509..510] -RRB-)))) (PP-LOC (IN:[511..513] in) (NP (DT:[514..515] a) (JJ:[516..522] female) (NN:[524..533] gastropod)))) (,:[533..534] ,) (VP (VBN:[535..541] called) (NP (-NONE-:[541..541] *)) (NP (NN:[542..549] imposex)))) (,:[549..550] ,) (VP (VBZ:[551..553] is) (ADVP (RB:[554..560] widely)) (VP (VBN:[561..571] attributed) (NP-1 (-NONE-:[571..571] *)) (PP-CLR (TO:[572..574] to) (NP (NP (DT:[575..578] the) (NN:[579..587] exposure)) (PP (TO:[588..590] to) (NP (NP (NML (NML (NN:[591..602] tributyltin)) (NML (-LRB-:[604..605] -LRB-) (NN:[605..608] TBT) (-RRB-:[608..609] -RRB-))) (NNS:[610..619] compounds)) (,:[619..620] ,) (VP (VBN:[621..625] used) (NP (-NONE-:[625..625] *)) (ADVP-LOC (NN:[626..631] world) (HYPH:[631..632] -) (RB:[632..636] wide)) (PP-LOC (IN:[637..639] in) (NP (NP (JJ:[640..651] antifouling) (NNS:[652..658] paints)) (PP (IN:[659..662] for) (NP (NNS:[663..668] ships)))))))))))) (.:[668..669] .))) ;sentence 5 Span:670..881 ;It has been hypothesized that the TBT-induced imposex is mediated by an ;increasing androgen level relative to the estrogen level, namely a decreased ;conversion of androgens to estrogens (i.e., aromatization). ;[705..708]:substance:"TBT" ;[754..762]:substance:"androgen" ;[786..794]:substance:"estrogen" ;[835..844]:substance:"androgens" ;[849..858]:substance:"estrogens" (SENT (S (NP-SBJ-2 (NP (PRP:[670..672] It)) (SBAR-3 (-NONE-:[672..672] *ICH*))) (VP (VBZ:[673..676] has) (VP (VBN:[677..681] been) (VP (VBN:[683..695] hypothesized) (NP-2 (-NONE-:[695..695] *)) (SBAR-3 (IN:[696..700] that) (S (NP-SBJ-1 (DT:[701..704] the) (ADJP (NN:[705..708] TBT) (HYPH:[708..709] -) (VBN:[709..716] induced)) (NN:[717..724] imposex)) (VP (VBZ:[725..727] is) (VP (VBN:[728..736] mediated) (NP-1 (-NONE-:[736..736] *)) (PP (IN:[737..739] by) (NP-LGS (NP (DT:[740..742] an) (VBG:[743..753] increasing) (NN:[754..762] androgen) (NN:[764..769] level)) (ADJP (JJ:[770..778] relative) (PP (TO:[779..781] to) (NP (NP (DT:[782..785] the) (NN:[786..794] estrogen) (NN:[795..800] level)) (,:[800..801] ,) (NP (ADVP (RB:[802..808] namely)) (NP (NP (DT:[809..810] a) (VBN:[811..820] decreased) (NN:[821..831] conversion)) (PP (IN:[832..834] of) (NP (NNS:[835..844] androgens))) (PP (TO:[846..848] to) (NP (NNS:[849..858] estrogens)))) (PRN (-LRB-:[859..860] -LRB-) (NP (ADVP (FW:[860..864] i.e.)) (,:[864..865] ,) (NP (NN:[866..879] aromatization))) (-RRB-:[879..880] -RRB-))))))))))))))) (.:[880..881] .))) ;sentence 6 Span:882..1114 ;In the present study, we tested this hypothesis by examining the effects of ;TBT or triphenyltin (TPT) on the aromatase activity in a cultured human ;granulosa-like tumor cell line, KGN, which was recently established by our ;group. ;[959..962]:substance:"TBT" ;[966..978]:substance:"triphenyltin" ;[980..983]:substance:"TPT" ;[993..1002]:substance:"aromatase" (SENT (S (PP (IN:[882..884] In) (NP (DT:[885..888] the) (JJ:[889..896] present) (NN:[897..902] study))) (,:[902..903] ,) (NP-SBJ (PRP:[904..906] we)) (VP (VBD:[907..913] tested) (NP (DT:[914..918] this) (NN:[920..930] hypothesis)) (PP-MNR (IN:[931..933] by) (S-NOM (NP-SBJ (-NONE-:[933..933] *)) (VP (VBG:[934..943] examining) (NP (NP (DT:[944..947] the) (NNS:[948..955] effects)) (PP (IN:[956..958] of) (NP (NP (NN:[959..962] TBT)) (CC:[963..965] or) (NP (NP (NN:[966..978] triphenyltin)) (NP (-LRB-:[979..980] -LRB-) (NN:[980..983] TPT) (-RRB-:[983..984] -RRB-)))))) (PP (IN:[985..987] on) (NP (DT:[988..991] the) (NN:[993..1002] aromatase) (NN:[1003..1011] activity))) (PP-LOC (IN:[1012..1014] in) (NP (NP (NP (DT:[1015..1016] a) (VBN:[1017..1025] cultured) (JJ:[1026..1031] human) (ADJP (NN:[1032..1041] granulosa) (HYPH:[1041..1042] -) (JJ:[1042..1046] like)) (NN:[1047..1052] tumor) (NN:[1053..1057] cell) (NN:[1058..1062] line)) (,:[1062..1063] ,) (NP (NN:[1064..1067] KGN))) (,:[1067..1068] ,) (SBAR (WHNP-1 (WDT:[1070..1075] which)) (S (NP-SBJ-1 (-NONE-:[1075..1075] *T*)) (VP (VBD:[1076..1079] was) (ADVP-TMP (RB:[1080..1088] recently)) (VP (VBN:[1089..1100] established) (NP-1 (-NONE-:[1100..1100] *)) (PP (IN:[1101..1103] by) (NP-LGS (PRP$:[1104..1107] our) (NN:[1108..1113] group))))))))))))) (.:[1113..1114] .))) ;sentence 7 Span:1115..1298 ;Treatment with more than 1000 ng/ml TBT compounds was very toxic to the ;cells and caused immediate cell death within 24 h, while 200 ng/ml was found ;to cause apoptosis of the cells. ;[1140..1144]:quantitative-value:"1000" ;[1145..1165]:quantitative-units:"ng/ml TBT compounds" ;[1234..1236]:quantitative-value:"24" ;[1237..1238]:quantitative-units:"h" ;[1246..1249]:quantitative-value:"200" ;[1250..1255]:quantitative-units:"ng/ml" (SENT (S (NP-SBJ (NP (NN:[1115..1124] Treatment)) (PP (IN:[1125..1129] with) (NP (NP (NP (QP (JJR:[1130..1134] more) (IN:[1135..1139] than) (CD:[1140..1144] 1000)) (NN:[1145..1147] ng)) (PP (SYM:[1147..1148] /) (NP (NN:[1148..1150] ml)))) (NP (NN:[1152..1155] TBT) (NNS:[1156..1165] compounds))))) (VP (VP (VBD:[1166..1169] was) (ADJP-PRD (RB:[1170..1174] very) (JJ:[1175..1180] toxic) (PP (TO:[1181..1183] to) (NP (DT:[1184..1187] the) (NNS:[1188..1193] cells))))) (CC:[1194..1197] and) (VP (VBD:[1198..1204] caused) (NP (JJ:[1205..1214] immediate) (NN:[1215..1219] cell) (NN:[1220..1225] death)) (PP-TMP (IN:[1226..1232] within) (NP (CD:[1234..1236] 24) (NN:[1237..1238] h)))) (,:[1238..1239] ,) (SBAR-ADV (IN:[1240..1245] while) (S (NP-SBJ-1 (NP (CD:[1246..1249] 200) (NN:[1250..1252] ng)) (PP (SYM:[1252..1253] /) (NP (NN:[1253..1255] ml)))) (VP (VBD:[1256..1259] was) (VP (VBN:[1260..1265] found) (S (NP-SBJ-1 (-NONE-:[1265..1265] *)) (VP (TO:[1266..1268] to) (VP (VB:[1269..1274] cause) (NP (NP (NN:[1275..1284] apoptosis)) (PP (IN:[1285..1287] of) (NP (DT:[1288..1291] the) (NNS:[1292..1297] cells)))))))))))) (.:[1297..1298] .))) ;sentence 8 Span:1299..1579 ;Treatment of the KGN cells for more than 48 h with 20 ng/ml TBT or TPT, ;which is a concentration level reported to cause imposex in marine species, ;did not affect cell proliferation but significantly suppressed the aromatase ;activity determined by a [(3)H]H(2)O release assay. ;[1341..1343]:quantitative-value:"48" ;[1344..1345]:quantitative-units:"h" ;[1351..1353]:quantitative-value:"20" ;[1354..1363]:quantitative-units:"ng/ml TBT" ;[1354..1359]...[1367..1370]:quantitative-units:"ng/ml"..."TPT" ;[1517..1526]:substance:"aromatase" ;[1553..1564]:substance:"[(3)H]H(2)O" (SENT (S (NP-SBJ (NP (NN:[1299..1308] Treatment)) (PP (IN:[1309..1311] of) (NP (DT:[1313..1316] the) (NN:[1317..1320] KGN) (NNS:[1321..1326] cells))) (PP-TMP (IN:[1327..1330] for) (NP (QP (JJR:[1331..1335] more) (IN:[1336..1340] than) (CD:[1341..1343] 48)) (NN:[1344..1345] h))) (PP-MNR (IN:[1346..1350] with) (NP (NP (NP (NP (CD:[1351..1353] 20) (NN:[1354..1356] ng)) (PP (SYM:[1356..1357] /) (NP (NN:[1357..1359] ml)))) (NP (NN:[1360..1363] TBT) (CC:[1364..1366] or) (NN:[1367..1370] TPT))) (,:[1370..1371] ,) (SBAR (WHNP-1 (WDT:[1372..1377] which)) (S (NP-SBJ-1 (-NONE-:[1377..1377] *T*)) (VP (VBZ:[1378..1380] is) (NP-PRD (NP (DT:[1381..1382] a) (NN:[1384..1397] concentration) (NN:[1398..1403] level)) (VP (VBN:[1404..1412] reported) (S (NP-SBJ (-NONE-:[1412..1412] *)) (VP (TO:[1413..1415] to) (VP (VB:[1416..1421] cause) (NP (NN:[1422..1429] imposex)) (PP-LOC (IN:[1430..1432] in) (NP (JJ:[1433..1439] marine) (NNS:[1440..1447] species)))))))))))))) (,:[1447..1448] ,) (VP (VP (VBD:[1449..1452] did) (RB:[1453..1456] not) (VP (VB:[1457..1463] affect) (NP (NN:[1465..1469] cell) (NN:[1470..1483] proliferation)))) (CC:[1484..1487] but) (VP (ADVP (RB:[1488..1501] significantly)) (VBD:[1502..1512] suppressed) (NP (NP (DT:[1513..1516] the) (NN:[1517..1526] aromatase) (NN:[1527..1535] activity)) (VP (VBN:[1537..1547] determined) (NP (-NONE-:[1547..1547] *)) (PP (IN:[1548..1550] by) (NP-LGS (DT:[1551..1552] a) (NN:[1553..1564] -LSB--LRB-3-RRB-H-RSB-H-LRB-2-RRB-O) (NN:[1565..1572] release) (NN:[1573..1578] assay))))))) (.:[1578..1579] .))) ;sentence 9 Span:1580..1732 ;Treatment with 20 ng/ml TBT compounds for 7 days also resulted in a ;reduction of the E2 production from Delta 4-androstenedione stimulated by ;db-cAMP. ;[1595..1597]:quantitative-value:"20" ;[1598..1617]:quantitative-units:"ng/ml TBT compounds" ;[1623..1624]:quantitative-value:"7" ;[1625..1629]:quantitative-units:"days" ;[1666..1668]:substance:"E2" ;[1685..1709]:substance:"Delta 4-androstenedione" ;[1724..1731]:substance:"db-cAMP" (SENT (S (NP-SBJ (NP (NN:[1580..1589] Treatment)) (PP (IN:[1590..1594] with) (NP (NP (CD:[1595..1597] 20) (NN:[1598..1600] ng)) (PP (SYM:[1600..1601] /) (NP (NN:[1601..1603] ml))) (NP (NN:[1604..1607] TBT) (NNS:[1608..1617] compounds)))) (PP (IN:[1619..1622] for) (NP (CD:[1623..1624] 7) (NNS:[1625..1629] days)))) (ADVP (RB:[1630..1634] also)) (VP (VBD:[1635..1643] resulted) (PP-CLR (IN:[1644..1646] in) (NP (NP (DT:[1647..1648] a) (NN:[1649..1658] reduction)) (PP (IN:[1659..1661] of) (NP (NP (NP (DT:[1662..1665] the) (NN:[1666..1668] E2) (NN:[1669..1679] production)) (PP (IN:[1680..1684] from) (NP (SYM:[1685..1690] Delta) (NN:[1692..1709] 4-androstenedione)))) (VP (VBN:[1710..1720] stimulated) (NP (-NONE-:[1720..1720] *)) (PP (IN:[1721..1723] by) (NP-LGS (NN:[1724..1731] db-cAMP))))))))) (.:[1731..1732] .))) ;sentence 10 Span:1733..1866 ;The changes in the aromatase activity by TBT compounds were associated with ;comparable changes in P450arom mRNA assessed by RT-PCR. ;[1752..1761]:substance:"aromatase" ;[1775..1788]:substance:"TBT compounds" ;[1832..1845]:substance:"P450arom mRNA" (SENT (S (NP-SBJ-1 (NP (DT:[1733..1736] The) (NNS:[1737..1744] changes)) (PP (IN:[1745..1747] in) (NP (DT:[1748..1751] the) (NN:[1752..1761] aromatase) (NN:[1762..1770] activity))) (PP (IN:[1772..1774] by) (NP (NN:[1775..1778] TBT) (NNS:[1779..1788] compounds)))) (VP (VBD:[1789..1793] were) (VP (VBN:[1794..1804] associated) (NP-1 (-NONE-:[1804..1804] *)) (PP-CLR (IN:[1805..1809] with) (NP (NP (NP (JJ:[1810..1820] comparable) (NNS:[1821..1828] changes)) (PP (IN:[1829..1831] in) (NP (NN:[1832..1840] P450arom) (NN:[1841..1845] mRNA)))) (VP (VBN:[1847..1855] assessed) (NP (-NONE-:[1855..1855] *)) (PP-MNR (IN:[1856..1858] by) (NP (NN:[1859..1861] RT) (HYPH:[1861..1862] -) (NN:[1862..1865] PCR)))))))) (.:[1865..1866] .))) ;sentence 11 Span:1867..2067 ;The luciferase activity of the P450arom promoter II (1 kb) decreased after ;the addition of 20 ng/ml TBT compounds in transfected KGN cells either in a ;basic state or in states stimulated by db-cAMP. ;[1871..1881]:substance:"luciferase" ;[1898..1906]:cyp450:"P450arom" ;[1907..1918]:substance:"promoter II" ;[1920..1921]:quantitative-value:"1" ;[1922..1924]:quantitative-units:"kb" ;[1959..1961]:quantitative-value:"20" ;[1962..1981]:quantitative-units:"ng/ml TBT compounds" ;[2059..2066]:substance:"db-cAMP" (SENT (S (NP-SBJ (NP (DT:[1867..1870] The) (NN:[1871..1881] luciferase) (NN:[1882..1890] activity)) (PP (IN:[1891..1893] of) (NP (NP (DT:[1894..1897] the) (NN:[1898..1906] P450arom) (NN:[1907..1915] promoter) (CD:[1916..1918] II)) (PRN (-LRB-:[1919..1920] -LRB-) (NP (CD:[1920..1921] 1) (NN:[1922..1924] kb)) (-RRB-:[1924..1925] -RRB-))))) (VP (VBD:[1927..1936] decreased) (PP-TMP (IN:[1937..1942] after) (NP (NP (DT:[1943..1946] the) (NN:[1947..1955] addition)) (PP (IN:[1956..1958] of) (NP (NP (NP (NP (CD:[1959..1961] 20) (NN:[1962..1964] ng)) (PP (SYM:[1964..1965] /) (NP (NN:[1965..1967] ml)))) (NP (NN:[1968..1971] TBT) (NNS:[1972..1981] compounds))) (PP (IN:[1982..1984] in) (NP (VBN:[1985..1996] transfected) (NN:[1997..2000] KGN) (NNS:[2001..2006] cells))) (PP (CC:[2008..2014] either) (PP (IN:[2015..2017] in) (NP (DT:[2018..2019] a) (JJ:[2020..2025] basic) (NN:[2026..2031] state))) (CC:[2032..2034] or) (PP (IN:[2035..2037] in) (NP (NP (NNS:[2038..2044] states)) (VP (VBN:[2045..2055] stimulated) (NP (-NONE-:[2055..2055] *)) (PP (IN:[2056..2058] by) (NP-LGS (NN:[2059..2066] db-cAMP)))))))))))) (.:[2066..2067] .))) ;sentence 12 Span:2068..2192 ;The Ad4BP-dependent increase in the luciferase activity of P450arom promoter ;II was also downregulated by such treatments. ;[2072..2077]:substance:"Ad4BP" ;[2105..2115]:substance:"luciferase" ;[2128..2136]:cyp450:"P450arom" ;[2137..2148]:substance:"promoter II" (SENT (S (NP-SBJ-1 (NP (DT:[2068..2071] The) (ADJP (NN:[2072..2077] Ad4BP) (HYPH:[2077..2078] -) (JJ:[2078..2087] dependent)) (NN:[2089..2097] increase)) (PP (IN:[2098..2100] in) (NP (NP (DT:[2101..2104] the) (NN:[2105..2115] luciferase) (NN:[2116..2124] activity)) (PP (IN:[2125..2127] of) (NP (NN:[2128..2136] P450arom) (NN:[2137..2145] promoter) (CD:[2146..2148] II)))))) (VP (VBD:[2149..2152] was) (ADVP (RB:[2153..2157] also)) (VP (VBN:[2159..2172] downregulated) (NP-1 (-NONE-:[2172..2172] *)) (PP (IN:[2173..2175] by) (NP-LGS (JJ:[2176..2180] such) (NNS:[2181..2191] treatments))))) (.:[2191..2192] .))) ;sentence 13 Span:2193..2355 ;These results indicate that TBT compounds inhibited the aromatase activity ;and also decreased the P450arom mRNA level at the transcriptional level in ;KGN cells. ;[2221..2234]:substance:"TBT compounds" ;[2250..2259]:substance:"aromatase" ;[2292..2305]:substance:"P450arom mRNA" (SENT (S (NP-SBJ (DT:[2193..2198] These) (NNS:[2199..2206] results)) (VP (VBP:[2207..2215] indicate) (SBAR (IN:[2216..2220] that) (S (NP-SBJ-1 (NN:[2221..2224] TBT) (NNS:[2225..2234] compounds)) (VP (VP (VBD:[2236..2245] inhibited) (NP (DT:[2246..2249] the) (NN:[2250..2259] aromatase) (NN:[2260..2268] activity))) (CC:[2269..2272] and) (VP (ADVP (RB:[2273..2277] also)) (VBD:[2278..2287] decreased) (NP-1 (-NONE-:[2287..2287] *)) (NP (DT:[2288..2291] the) (NML (NN:[2292..2300] P450arom) (NN:[2301..2305] mRNA)) (NN:[2306..2311] level)) (PP (IN:[2312..2314] at) (NP (DT:[2316..2319] the) (JJ:[2320..2335] transcriptional) (NN:[2336..2341] level))) (PP-LOC (IN:[2342..2344] in) (NP (NN:[2345..2348] KGN) (NNS:[2349..2354] cells)))))))) (.:[2354..2355] .))) ;sentence 14 Span:2356..2521 ;The direct inhibitory effect of TBT compounds on the aromatase activity may ;therefore partly explain the induction of imposex by these compounds in ;female species. ;[2388..2402]:substance:"TBT compounds" ;[2410..2419]:substance:"aromatase" ;[2493..2502]:substance:"compounds" (SENT (S (NP-SBJ (NP (DT:[2356..2359] The) (JJ:[2360..2366] direct) (JJ:[2367..2377] inhibitory) (NN:[2378..2384] effect)) (PP (IN:[2385..2387] of) (NP (NN:[2388..2391] TBT) (NNS:[2393..2402] compounds))) (PP (IN:[2403..2405] on) (NP (DT:[2406..2409] the) (NN:[2410..2419] aromatase) (NN:[2420..2428] activity)))) (VP (MD:[2429..2432] may) (ADVP (RB:[2433..2442] therefore)) (ADVP (RB:[2443..2449] partly)) (VP (VB:[2450..2457] explain) (NP (NP (DT:[2458..2461] the) (NN:[2462..2471] induction)) (PP (IN:[2473..2475] of) (NP (NN:[2476..2483] imposex))) (PP (IN:[2484..2486] by) (NP (DT:[2487..2492] these) (NNS:[2493..2502] compounds))) (PP-LOC (IN:[2503..2505] in) (NP (JJ:[2506..2512] female) (NNS:[2513..2520] species)))))) (.:[2520..2521] .))) ;section 15 Span:2522..2552 ;Copyright 2001 Academic Press. (SEC (FRAG (NN:[2522..2531] Copyright) (CD:[2532..2536] 2001) (NNP:[2537..2545] Academic) (NNP:[2546..2551] Press) (.:[2551..2552] .))) ;section 16 Span:2556..2601 ;PMID: 11708799 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[2556..2560] PMID) (::[2560..2561] :) (CD:[2562..2570] 11708799) (NN:[2571..2572] -LSB-) (NNP:[2572..2578] PubMed) (::[2579..2580] -) (NN:[2581..2588] indexed) (IN:[2589..2592] for) (NNP:[2593..2601] MEDLINE-RSB-)))